Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX
Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX
The goal of this research is to study an intervention, which the investigators call
 "Supportive Oncology Care at Home," that entails both remote patient monitoring (e.g.
 patient-reported symptoms, home monitored vital signs, and body weight) and a Medically Home
 care model (e.g. triggers for phone calls and visits to patients' homes to address and manage
 any concerning issues identified). Specifically, the investigators will conduct a single arm
 pilot study (N=20) in patients with pancreatic cancer who sign consent for parent trial of
 neoadjuvant FOLFIRINOX (18-179) receiving preoperative FOLFIRINOX to assess the feasibility
 and acceptability of Supportive Oncology Care at Home.
Preoperative treatment can cause significant morbidity and often result in hospitalizations.
 Patients receiving preoperative FOLFIRINOX often experience numerous side effects, including
 nausea, vomiting, diarrhea, fatigue, fever, neuropathy, and loss of appetite. Frequently,
 patients require hospital admissions to help address uncontrolled symptoms related to their
 cancer and side effects related to the treatment,

 Interventions targeting patients' symptoms and delivering care to patients at their homes
 have the potential to improve patient outcomes. Studies show that interventions targeting
 patients' symptoms can improve symptom management, enhance quality of life (QOL), and prevent
 hospitalizations.

 Medically Home interventions have shown the potential to enhance patient outcomes. The
 Medically Home model of care is an alternative to a hospital admission for acute care and
 treatment of a clinical condition. Medically Home interventions entail providing medical care
 to acutely ill patients in their home. In addition, research in the general medicine
 literature has demonstrated that interventions involving remote patient monitoring with
 'triggers' for visits to patients' homes for worrisome symptoms can enhance care outcomes.

 Although this research demonstrates promising results, these studies have not been conducted
 among patients with cancer. Notably, the prior work involving home monitoring with visits as
 needed has lacked patient-reported outcomes, such as symptom monitoring. Thus, efforts are
 needed to develop and test interventions containing both symptom monitoring and the potential
 for home visits when necessary in a population of patients with cancer.
Inclusion Criteria:

 -  Age 18 or older

 -  Within three weeks of signing consent for parent trial of neoadjuvant FOLFIRINOX

 -  Planning to receive care at Massachusetts General Hospital

 -  Ability to read and respond to questions in English

 -  Residing within 50 miles of Massachusetts General Hospital

 Exclusion Criteria:

 -Uncontrolled psychiatric illness or impaired cognition